Physician profile
Anna Gorelik
NPI 1407139801
$14,655.30
in general payments reported to CMS, 2019-2025
41 companies · $4,076 in 2025
The $4,076 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,510 · 2022: $2,641 · 2023: $2,942 · 2024: $2,486 · 2025: $4,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,705 · Consulting Fee: $1,344 · Education: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,704.64 |
| Consulting Fee | $1,344.00 |
| Education | $455.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,867.12 | 2021-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $1,605.56 | 2021-2025 | Tezspire, Airsupra, Breztri |
| Regeneron Pharmaceuticals, INC. | $1,463.01 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,388.01 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,311.63 | 2021-2025 | Dupixent |
| Harmony Biosciences LLC | $1,049.01 | 2021-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $883.93 | 2021-2025 | Stiolto Respimat, Ofev, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $593.43 | 2021-2025 | |
| Electromed, INC. | $500.43 | 2021-2025 | Smartvest |
| Genentech USA, INC. | $394.42 | 2021-2024 | Xolair |
| Mylan Specialty L.P. | $386.97 | 2021-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $319.71 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $229.81 | 2021-2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $224.49 | 2021-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $220.71 | 2025 | Yupelri |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $220.50 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Verona Pharma, INC. | $216.81 | 2025 | Ohtuvayre |
| Insmed, INC. | $189.22 | 2021-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $182.69 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Amgen INC. | $165.06 | 2022-2023 | Tezspire |
| Paratek Pharmaceuticals, INC. | $144.34 | 2023-2024 | Nuzyra |
| United Therapeutics Corporation | $128.42 | 2021-2023 | Tyvaso, Orenitram |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $92.07 | 2023-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $90.27 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $75.87 | 2024-2025 | Lumryz |
| Advanced Respiratory, INC | $73.87 | 2021 | |
| Axsome Therapeutics, INC. | $68.05 | 2024-2025 | Sunosi |
| Baxter Healthcare | $63.51 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $60.02 | 2021-2023 | |
| Inspire Medical Systems, INC. | $56.02 | 2025 | Inspire |
| Vifor Pharma, INC. | $52.63 | 2024-2025 | Zemaira, Veltassa |
| Pfizer INC. | $39.61 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $33.63 | 2025 | Acthar |
| Teva Pharmaceuticals USA, INC. | $29.20 | 2021 | |
| Idorsia Pharmaceuticals US INC | $27.22 | 2022 | |
| Sunovion Pharmaceuticals INC. | $26.54 | 2021 | |
| Lilly USA, LLC | $25.86 | 2025 | Mounjaro, Zepbound |
| Leo Pharma INC. | $21.33 | 2025 | Adbry |
| Janssen Pharmaceuticals, INC | $17.72 | 2023 | Xarelto |
| Hikma Pharmaceuticals USA | $17.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Gorelik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.